CombiMatrix, Clarient to market and sell cancer test
Jan 31 (Reuters) - CombiMatrix Corp (CBMX.O: Quote, Profile, Research) and Clarient Inc (CLRT.O: Quote, Profile, Research) said they would jointly market and sell a cancer test called HemeScan.
HemeScan test will be marketed by Clarient to pathologists, oncologists and patients, CombiMatrix said in a statement.
The HemeScan test is a comprehensive test which enables prognosis at the time of diagnosis in the treatment and care of chronic lymphocytic leukemia patients. (Reporting by Bhaswati Mukhopadhyay in Bangalore; Editing by Amitha Rajan)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Consulting Opportunity; Healthcare Expertise Required
Details: ...topic area experts for paid consultations. We are seeking Healthcare professionals with advanced knowledge and insights from diverse...
Clinical Research Solutions and Healthcare Compliance Associate
Details: ...leading academic institutions, healthcare organizations, and the law...Clinical Research Solutions/Healthcare Compliance team is a national...
CEO - Chief Executive Officer - Healthcare - Hospital
Details: ...has worked in the healthcare industry either...level, within the healthcare vertical. Utilizing...for hospitals and healthcare systems totaling...
Healthcare Sales Representative
Details: ...commercial business, healthcare, and government...salesperson to cover the healthcare and business sector...consideration in targeted healthcare building and renovation...
Sphere
Endgame plan
Deadly tornadoes hit U.S.
